Blood Cancers
Blood Cancers
Advertisement
Rebecca AraujoASH 2024 | December 5, 2024
Area Deprivation Index was associated with overall survival in both Black and Hispanic patients.
Read More
Rebecca AraujoASH 2024 | December 3, 2024
Black, Hispanic, and Asian patients were underrepresented in trials compared with national lymphoma data.
Rebecca AraujoASH 2024 | December 2, 2024
Families reported the direct cash support program offered them the “ability to spend more time at their child’s ...
Tamara ThomasASH 2024 | December 1, 2024
Despite delays to infusion, response rates to CAR-T were comparable across racial groups.
Tamara ThomasASH 2024 | November 30, 2024
The proportion of myeloma cases linked to BMI and diabetes was higher in Black patients than White patients.
Tamara ThomasASH 2024 | November 30, 2024
Patients who were Black or female were more likely to refuse treatment for multiple myeloma.
Tamara ThomasBlood Cancers | December 6, 2023
Researchers found that Hispanic people were more likely to develop and die from ALL than Black and White people.
Cailin ConnerMultiple Myeloma | November 30, 2023
Hispanic patients with multiple myeloma had lower overall response rates to idecabtagene vicleucel.
Cailin ConnerBlood Cancers | November 28, 2023
Advanced age, financial constraints contribute to higher discontinuation rates among elderly Medicare beneficiaries.
Cailin ConnerBlood Cancers | November 15, 2023
Breastfeeding has a protective effect against acute lymphoblastic leukemia in young children.
Cailin ConnerBlood Cancers | November 1, 2023
Study suggests significant associations between nonchromosomal birth defects and childhood leukemia.
Cailin ConnerBlood Cancers | October 16, 2023
Vitamin C and D supplementation for the treatment of AML, was associated with reduced infection rates.
Patrick DalyMultiple Myeloma | October 17, 2023
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
Patrick DalyMultiple Myeloma | October 17, 2023
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Patrick DalyMultiple Myeloma | October 17, 2023
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patrick DalyMultiple Myeloma | October 17, 2023
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
Cailin ConnerBlood Cancers | October 2, 2023
The prognosis for induction failure in childhood T-cell ALL remains unfavorable despite advancements in treatment.
Patrick DalyMultiple Myeloma | October 17, 2023
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
Patrick DalyMultiple Myeloma | October 17, 2023
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Patrick DalyMultiple Myeloma | October 17, 2023
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Advertisement
Advertisement
Advertisement
Latest News

December 24, 2024